Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Neoplasms 4Breast Neoplasms 3Prostatic Neoplasms 2Melanoma 2Healthy Participants 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumor 2cMET-dysregulated Advanced Solid Tumors 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Solid Tumor 1Neoplastic Cells, Circulating 1Liver Cirrhosis 1Drug-drug Interaction,SHR3680 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Melanoma × Digoxin × Clear all
NCT02138292 2018-05-15

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

University of Texas Southwestern Medical Center

Phase 1 Completed
27 enrolled
Dermatologic

Melanoma

NCT01765569 2015-09-23

A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Hoffmann-La Roche

Phase 1 Completed
29 enrolled 15 charts
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡